The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Supply and clinical application of Actinium-225 and Bismuth-213.
Open accessAbstract
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Worldwide, only three sources of 229Th are available (81).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Self-citationTargeted α particle immunotherapy for myeloid leukemia
Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472
Kratochwil, C., Bruchertseifer, F., Rathke, H. G., Hohenfellner, M., Giesel, F. L., Haberkorn, U., & Morgenstern, A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.203539 · Cited by 429
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 418
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
Sathekge, M. M., Bruchertseifer, F., Knoesen, O., Reyneke, F., Lawal, I. O., Lengana, T., Davis, C., Mahapane, J., Corbett, C., Vorster, M., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4167-0 · Cited by 361
Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N. D., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S. M., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 272
Production of Ac-225 from Th-229 for Targeted α Therapy
Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215
Self-citationCordier, D., Forrer, F., Bruchertseifer, F., Morgenstern, A., Apostolidis, C., Good, S., Müller‐Brand, J., Mäcke, H. R., Reubi, J. C., & Merlo, A. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1385-5 · Cited by 208
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.229229 · Cited by 196
Research works printed but not linked: 3
- Kratochwil, 2015, Ac-225-DOTATOC - dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors, Eur J Nucl Med Mol Imaging, 42, S36
- Czerwinski K.Production of 225Ac from 229Th. Report on joint IAEA-JRC workshop “Supply of Actinium-225”. IAEA, Vienna, 2018. http://www-naweb.iaea.org/napc/iachem/working_materials.html
- Koning, 2013, Tendl-2012, NRG, Petten
Cited by
Sorted by citations
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Filosofov, D. V., Kurakina, E. S., & Radchenko, V. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.12.001 · Cited by 342
Production and Supply of α-Particle–Emitting Radionuclides for Targeted α-Therapy
Radchenko, V., Morgenstern, A., Jalilian, A. R., Ramogida, C. F., Cutler, C. S., Duchemin, C., Hoehr, C., Haddad, F., Bruchertseifer, F., Gausemel, H., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261016 · Cited by 142
“61 min), which also can be applied in TAT (19).”
BackgroundBismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
“Also, the transient equilibrium of the 225Ac-213Bi permits elution at approximately every 3 h [40].”
BackgroundMorgan, K. A., Rudd, S. E., Noor, A., & Donnelly, P. S. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00456 · Cited by 101
Abou, D. S., Thiele, N. A., Gutsche, N. T., Villmer, A., Zhang, H., Woods, J. J., Baidoo, K. E., Escorcia, F. E., Wilson, J. J., & Thorek, D. L. J. (2021) · Chemical Science · doi:10.1039/d0sc06867e · Cited by 100
Metadata
- Authors
- Morgenstern, A., Apostolidis, C., & Bruchertseifer, F.
- Affiliations
- European Commission (BE)
- Corresponding author
- Morgenstern, Alfred
- Venue
- Seminars in Nuclear Medicine
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 50
- Issue
- 2
- Pages
- 119-123
- ISSN
- 0001-2998 (ISSN-L)
- PMC
- PMC7082773
- OpenAlex
- W3007334567
- Cited by
- 141
- References
- 45
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 23 · 2023: 19 · 2022: 15 · 2021: 29 · 2020: 8
- FWCI
- 2.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Seminars in Nuclear Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Funders
- Joint Research Centre
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
- Physical Sciences › Physics and Astronomy › Radiation › Radioactive Decay and Measurement Techniques
- Keywords
- actinium-225, bismuth-213, targeted alpha therapy, prostate cancer, radioisotope production, radionuclide supply, alpha-emitting radionuclides, neuroendocrine tumors, brain tumors, leukemia, bladder cancer
- MeSH terms
- Actinium, Bismuth, Humans, Isotope Labeling, Male, Prostatic Neoplasms, Radioisotopes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
